Interaksi Darunavir dan Elvitegravir, kobisistat, emtrisitabin, dan tenofovir

Darunavir dan Elvitegravir, kobisistat, emtrisitabin, dan tenofovir: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir (Genvoya) · berlaku sejak 2025-02-03

Mayor

GENVOYA should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Mayor

Not Recommended with Other Antiretroviral Medications GENVOYA is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration of GENVOYA with other antiretroviral medications for treatment of HIV-1 infection should be avoided.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Complete information regarding potential drug-drug interactions with other antiretroviral medications is not provided [see Contraindications (4) , Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Coadministration of GENVOYA with other drugs that inhibit CYP3A may decrease the clearance and increase the plasma concentration of cobicistat.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including emtricitabine, a component of GENVOYA, and tenofovir DF, another prodrug of tenofovir, alone or in combination with other antiretrovirals.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Dari label Darunavir (PREZISTA) · berlaku sejak 2025-08-29

Moderat

Co-administration of darunavir and ritonavir and other drugs that inhibit CYP3A, or P-gp may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (see Table 10 ).

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

If the antiretroviral regimen must be withheld for a prolonged period, consideration should be given to initiating a revised regimen that does not include a CYP3A or P-gp inhibitor.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

The specific recommendations are based on indication, renal function, and effect of the co-administered P-gp inhibitors on the concentration of dabigatran or edoxaban.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Tanpa interaksi

…PREZISTA/ritonavir is co-administered with the following medications: atazanavir, dolutegravir, efavirenz, etravirine, nevirapine, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, emtricitabine/tenofovir alafenamide, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine), pitavastatin, raltegravir, ranitidine, or rilpivirine.

Interaksi obatmenyebut Elvitegravir, kobisistat, emtrisitabin, dan tenofovirLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.